

(51) International Patent Classification:

A61K 39/095 (2006.01)

(21) International Application Number:

PCT/IB2013/051791

(22) International Filing Date:

6 March 2013 (06.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/609,257 9 March 2012 (09.03.2012) US

(71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: ANDERSON, Annaliesa Sybil; 49 Hillcrest Drive, Upper Saddle River, New Jersey 07458 (US). HOISETH, Susan Kay; 17 Coe Farm Road, Montebello, New York 10901 (US). JANSEN, Kathrin Ute; 57 Heather Court, Allendale, New Jersey 07401 (US). MORAN, Justin Keith; 682 Sierra Vista Lane, Valley Cottage, New York 10989 (US). RUPPEN, Mark E.; 6 Lea Court, Garnerville, New York 10923 (US).

(74) Agent: KLEIMAN, Gabriel L.; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF

FIG. 9A

		1		60
A05	(1)	CSSGSGSGGGVAAIDIGTGLADALTAPLDHKDKGLSLTLDQSVRKNEKLLAAQGAET		
A12	(1)	CSSG---GGGVAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLLAAQGAET		
A22	(1)	CSSG---GGGVAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLLAAQGAET		
A62	(1)	CSSG---GGGVAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLLAAQGAET		
B09	(1)	CSSG---GGGVAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLLAAQGAET		
B24	(1)	CSSG---GGGVAADIGAGLADALTAPLDHKDKSLQSLTLDQSVRKNEKLLAAQGAET		
Consensus	(1)	CSSG GGGVAADIGAGLADALTAPLDHKDKGLQSLTLDQSVRKNEKLLAAQGAET		
		61		120
A05	(61)	SKVGDKDNLSLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		
A12	(57)	YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		
A22	(57)	YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		
A62	(57)	YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		
B09	(57)	YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		
B24	(57)	YGNGD---SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		
Consensus	(61)	YGNGD SLNTGKLKNDKVSFRDFIRQIEVDGQITTLASGEFQIYKQDHSALVALQTEK		

(57) Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from *Neisseria meningitidis* serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.